Table 2.

Correlation between miR-101-2 expression and clinical parameters in BC from the TCGA data.

Clinicopathological features		Cases	MiR-101-2 expression		P value
			Low	High
Age	≥50	563	287	276	0.150
	<50	218	104	114
Gender	Female	772	385	387	0.485
	Male	9	6	3
T	T1–T2	657	343	314	0.008
	T3–T4	123	48	75
N	N0	373	200	173	0.029
	N1–N3	398	187	211
M	M0	610	343	267	0.017
	M1	9	2	7
Stage	I–II	587	298	289	0.129
	III–IV	186	88	98
ER	Positive	565	275	290	0.058
	Negative	170	88	82
PR	Positive	502	245	257	0.250
	Negative	231	118	113
HER2	Positive	99	54	55	0.481
	Negative	397	207	190

T – tumor stage; N – lymph node stage; M – metastasis stage; ER – estrogen receptor; PR – progesterone receptor; HER2 – human epidermal growth factor receptor 2. The median was chosen as the cut-off value because of the skewed distribution of the expression data.